Bailard’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bailard’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,854	Closed	-$227K	–	822
2025 Q3	$227K	Buy	+5,854	New	+$190K	﹤0.01%	702
2022 Q1	–	Sell	-25,900	Closed	-$305K	–	770
2021 Q4	$305K	Buy	+25,900	New	+$318K	0.01%	532

Other funds holding KNSA

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bailard's KNSA Position: Q4 2025 in Review

Bailard sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2025, closing a stake of 5,854 shares — an estimated $227K sold.

Bailard first reported a position in KNSA in Q4 2021 and held it in 2 quarters. The position peaked at $305K in Q4 2021. 224 funds tracked by Wall St. Rank hold KNSA as of Q4 2025.

Bailard reported no remaining Kiniksa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bailard sold 5,854 Kiniksa Pharmaceuticals shares in Q4 2025, an estimated $227K.
Bailard first reported a position in Kiniksa Pharmaceuticals in Q4 2021 and held it in 2 quarters.
Bailard's Kiniksa Pharmaceuticals position peaked at $305K in Q4 2021.
224 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2025.

Based on Bailard's 13F filing for Q4 2025, filed 4 Feb 2026.